Enzyme inhibition assays further highlight T. willdenowii’s strong activity against acetylcholinesterase (96.4%), as well as tyrosinase and α-glucosidase, suggesting therapeutic potential in the treatment of neurodegenerative diseases and type 2 diabetes. Here, TYR is linked to type 2 diabetes mellitus.